Alpha 2.0
Login Register
» Authors » Hassan Alkhateeb

Hassan Alkhateeb

Explore the profile of Hassan Alkhateeb including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 73
Citations 296
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
Ayalew Tefferi
Aref Al-Kali
Naseema Gangat
William J Hogan
Mark R Litzow
Animesh Pardanani
Mrinal M Patnaik
Kebede H Begna
Mithun Shah
Abhishek Mangaonkar
Published In
Am J Hematol
Blood Cancer J
Haematologica
Bone Marrow Transplant
Blood Adv
Affiliations
Soon will be listed here.
Recent Articles
11.
Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study
Herasevich S, Schulte P, Hogan W, Alkhateeb H, Zhang Z, White B, et al.
Am J Respir Crit Care Med . 2023 Dec; 209(5):543-552. PMID: 38051944
Pulmonary complications contribute significantly to nonrelapse mortality following hematopoietic stem cell transplantation (HCT). Identifying patients at high risk can help enroll such patients into clinical studies to better understand, prevent,...
12.
Mast cell cytomorphology and treatment outcome in mast cell leukemia
Tefferi A, Pardanani A, Al-Kali A, Alkhateeb H, McCullough K, Patnaik M, et al.
Am J Hematol . 2023 Sep; 99(1):E5-E8. PMID: 37732882
No abstract available.
13.
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
Abdelmagid M, Al-Kali A, Litzow M, Begna K, Hogan W, Patnaik M, et al.
Blood Cancer J . 2023 Aug; 13(1):122. PMID: 37567878
We surveyed the performance of ponatinib, as salvage therapy, in a real-world setting of chronic phase chronic myeloid leukemia (CML-CP). Among 55 consecutive patients (median age 49 years) with relapsed/refractory...
14.
IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience
Gangat N, Ajufo H, Abdelmagid M, Karrar O, McCullough K, Badar T, et al.
Br J Haematol . 2023 Aug; 203(3):e87-e92. PMID: 37537750
No abstract available.
15.
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, et al.
Haematologica . 2023 Aug; 109(1):187-292. PMID: 37534525
No abstract available.
16.
Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases
Gangat N, Alkhateeb H, Reichard K, Tefferi A
Am J Hematol . 2023 Jul; 98(10):E276-E280. PMID: 37470368
No abstract available.
17.
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Tefferi A, Alkhateeb H, Gangat N
Blood Cancer J . 2023 Jul; 13(1):108. PMID: 37460550
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as "blast-phase MPN", is the most feared disease complication, with incidence estimates of 1-4% for essential thrombocythemia, 3-7% for polycythemia vera,...
18.
Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era
Badar T, Alkhateeb H, Aljurf M, Kharfan-Dabaja M
Curr Res Transl Med . 2023 Apr; 71(2):103392. PMID: 37121211
Before the advent of tyrosine kinase inhibitors (TKI) the outcome of Philadelphia chromosome positive (Ph) acute lymphoblastic leukemia (ALL) was dismal. The TKI combination with induction regimens has greatly improved...
19.
Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases
Gangat N, Abdallah M, Szuber N, Saliba A, Alkhateeb H, Al-Kali A, et al.
Am J Hematol . 2023 Apr; 98(7):E165-E167. PMID: 37073574
No abstract available.
20.
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Abdallah M, McCullough K, Ilyas R, Begna K, Al-Kali A, Litzow M, et al.
Blood Cancer J . 2023 Mar; 13(1):35. PMID: 36907917
No abstract available.